metaMe Health

metaMe Health develops prescription digital therapeutics (PDTs) that deliver non-pharmacological interventions for gastrointestinal conditions. The company's core product, Regulora, provides an FDA-cleared digital program utilizing gut-directed hypnotherapy for the treatment of Irritable Bowel Syndrome (IBS). This therapeutic approach aims to address the mind-gut connection through a digitally accessible platform, offering an alternative to traditional medication.

The company was founded by Danny Bernstein, who serves as Chief Product Officer. Bernstein's personal struggle with inflammatory bowel disease and irritable bowel syndrome led him to discover the efficacy of gut-directed hypnotherapy. His firsthand experience fueled the insight and mission to make this effective, yet often inaccessible, treatment more widely available through a convenient digital format.

metaMe Health targets individuals suffering from functional gastrointestinal disorders, particularly those seeking drug-free alternatives. The company envisions a future where digital interventions play a significant role in managing chronic conditions, thereby increasing accessibility to effective behavioral therapies. They are focused on expanding the use of clinically validated digital therapeutics to improve patient outcomes and transform the landscape of chronic pain and disorder management.

metaMe Health is a U.S. digital therapeutics company that develops prescription digital therapeutics (PDTs) using automated gut‑directed hypnotherapy and other brain‑gut behavioral protocols to treat gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS) and functional dyspepsia (FD). [1][4]

High‑Level Overview

• metaMe Health builds prescription digital therapeutics (software-as-a-medical-device) — notably Regulora® (an FDA‑authorized PDT for abdominal pain associated with IBS in adults) and other gut‑directed hypnotherapy products — designed to be prescribed confidentially and completed at home as non‑drug treatment options for chronic GI conditions.[4][1]
  - The company serves patients with chronic digestive disorders, gastroenterologists and other prescribers, and payers/employers seeking clinically validated, cost‑effective alternatives to drug or in‑person therapy.[1][4]
  - metaMe’s products solve access, stigma, and scalability problems for behavioral GI treatments by packaging validated hypnotherapy protocols into automated, clinician‑prescribable digital programs that can reach large patient populations remotely.[1][4]
  - Growth momentum: metaMe obtained FDA authorization for Regulora and has commercial partnerships (for example with Indegene) to scale launch and distribution; it has also licensed additional GDH protocols and is pursuing expanded indications, signalling an active commercialization and pipeline expansion phase.[4][3][5]

Origin Story

• Founding and leadership: metaMe was founded and led by health‑tech entrepreneurs including Danny Bernstein (founder and chief product officer) and Tim Rudolphi (CEO during commercial launches referenced in press) with ties to clinical collaborators and investors such as Hyde Park Angels.[1][2][4]
  - How the idea emerged: the company’s focus on gut‑directed hypnotherapy grew from patient and clinical recognition that GDH is effective but under‑available; metaMe licensed established GDH protocols (e.g., from Dr. Olafur Palsson) and digitized them into fully automated PDTs to broaden access.[1][5]
  - Early traction / pivotal moments: pivotal milestones include licensing validated GDH protocols, conducting clinical development with decentralized trial technology partners (e.g., Curebase helped in the FDA clearance pathway), and achieving FDA authorization for Regulora followed by commercial partnerships to launch the product.[3][4]

Core Differentiators

• Clinically validated protocols: metaMe licenses established, research‑backed gut‑directed hypnotherapy protocols developed by recognized clinical researchers rather than inventing unvalidated content.[1][5]
  - Regulatory achievement: Regulora is presented as the first FDA‑authorized PDT specifically for IBS‑related abdominal pain in adults, giving metaMe regulatory differentiation and reimbursement/clinical adoption advantages.[4]
  - Fully automated, prescription model: treatments are delivered as fully automated audio/interactive programs that do not require a live hypnotherapist, improving scalability and privacy for users.[1][5]
  - Commercial partnerships and launch capability: metaMe has partnered with commercialization and omnichannel firms (e.g., Indegene) to accelerate provider and payer education and market access.[4]
  - Focused GI portfolio & pipeline: beyond IBS, metaMe has pursued licensing and development for functional dyspepsia and other GI indications, creating a focused therapeutic franchise in digestive health.[5]

Role in the Broader Tech & Health Landscape

• Trend alignment: metaMe rides two convergent trends — growth of prescription digital therapeutics/SaMD and increasing recognition of brain‑gut connections and behavioral treatments for functional GI disorders — positioning it where digital delivery and evidence‑based behavioral medicine meet.[1][4]
  - Timing and market forces: large unmet need (tens of millions with symptomatic IBS/FD), limited access to specialized GI behavioral care, payer interest in non‑drug cost containment, and regulatory pathways for PDTs favor adoption of validated digital hypnotherapy.[4][1]
  - Ecosystem influence: by securing FDA authorization and commercial partnerships, metaMe helps legitimize hypnotherapy‑based digital treatments in mainstream clinical practice and may lower barriers for other PDT developers targeting functional disorders.[4][3]

Quick Take & Future Outlook

• Near term: expect metaMe to focus on commercial rollout of Regulora (provider/payer engagement, patient acquisition via prescribing channels), scaling partnerships, and pursuing reimbursement pathways supported by its FDA authorization and real‑world evidence.[4][3]
  - Pipeline and expansion: metaMe’s licensing of additional GDH protocols and stated plans for PDTs in FD, heartburn, and ulcerative colitis indicate a strategy to build a GI‑focused PDT portfolio that can increase lifetime value per patient and broader market reach.[5][1]
  - Risks and catalysts: adoption will depend on payer coverage, clinician prescribing behavior, and the company’s ability to demonstrate cost‑effectiveness and sustained clinical benefit in real‑world populations; regulatory clearances and successful commercialization partnerships are key catalysts.[4][3]
  - Influence: if metaMe scales successfully, it could accelerate acceptance of automated, prescription behavioral therapies for functional conditions and serve as a model for specialty PDT franchises.

If you’d like, I can (a) draft a one‑page investor‑style summary, (b) extract citations and dates for the FDA authorization and key partnerships, or (c) build a short competitive map of other PDTs in functional GI.